Table 1.
Study characteristics.
| Study | Design | N | Age in TKI group (range) | TKI | Comparator | Myeloablative conditioning | CR at transplantb | High-risk cytogenetics | Length of follow-up |
|---|---|---|---|---|---|---|---|---|---|
| Burchert et al. (31) | Randomized phase 2 | 83 | 54 (23–74) |
Sorafenib | Placebo | TKI: 42%, Placebo: 47% |
TKI: 63%, placebo: 48% |
TKI: 2%, Placebo: 8% |
42 months |
| Brunner et al. (30) | Retrospective | 81 | 55 (20–74) |
Sorafenib | No TKI | TKI: 54%, No: 49% |
100% (CR1) | 8% | 27 months |
| Schlenk et al. (29) | Prospective phase 2, propensity score matching with historical controls |
116a | 54 (18–70) |
Midostaurin | Historical control | NR | TKI: 61%, control: 43% | NR | 24 months |
| Xuan et al. (28) | Randomized phase 3 |
202 | 35 (26–42) |
Sorafenib | No TKI | 100% | TKI: 73%, no: 77% |
TKI: 7%,no: 5% | 21 months |
| Xuan et al. (27) | Retrospective | 82 | 37 (15–55) |
Sorafenib | No TKI | 100% | 77% | TKI: 6%, no: 1% |
59 months |
| Maziarz et al. (32) | Randomized phase 2 |
60 | 18–70c | Midostaurin | No TKI | 100% | NR | NR | 18 months |
| Shi et al. (33) | Retrospective | 56 | 24 (14–62) |
Sorafenib | No TKI | 100% | 100% | 17% | 24 months |
N, number; TKI, tyrosine kinase inhibitor; HSCT, hematopoietic stem-cell transplantation; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; CR, complete remission; NR, not reported.
a
The original number of patients in the study was 284, here we report on the subgroup analyses of patients that actually underwent midostaurin maintenance after stem-cell transplantation or not.
b
As reported in the patient characteristics of the trials.
c
Inclusion criteria, age distribution not given.